Xigadap 10 Tablet contains Dapagliflozin 10 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dapagliflozin acts by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism is independent of insulin secretion or action, making it effective in various stages of type 2 diabetes. Xigadap 10 may be used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin. Clinical studies have demonstrated its efficacy in reducing HbA1c, fasting plasma glucose, and body weight, with additional benefits on blood pressure reduction. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Caution is advised in patients with renal impairment, as efficacy diminishes with declining kidney function. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of renal function and glycemic parameters is recommended during therapy with Xigadap 10 Tablet to ensure safety and optimal therapeutic outcomes.